{"meta":{"query_hash":"8a12679ee9bf","filters":{"venue":"Clinical Medicine Insights Urology"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/8a12679ee9bf","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Medicine+Insights+Urology"},"results":[{"id":"W2039213214","doi":"10.4137/cmu.s6425","title":"Clinical Use of Tolterodine Extended Release in Overactive Bladder","year":2012,"lang":"en","type":"article","venue":"Clinical Medicine Insights Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Tolterodine; Tolerability; Overactive bladder; Medicine; Urology; Extended release; Adverse effect; Internal medicine; Pharmacology; Alternative medicine","score_opus":0.20033428982238885,"score_gpt":0.4743489449808295,"score_spread":0.2740146551584407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039213214","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00848041,0.9856997,0.00018434302,0.00068831985,0.0001970415,0.00006774213,0.00038184345,0.000008604038,0.004291894],"genre_scores_gemma":[0.11514592,0.8793118,0.0012842979,0.0016050487,0.00082262343,0.000093460054,0.0005665226,0.000011619134,0.001158689],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981365,0.0006863543,0.00064029545,0.00012794843,0.00037007115,0.00003885611],"domain_scores_gemma":[0.98601717,0.009709238,0.003229372,0.00011029215,0.0007735466,0.0001603831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021503812,0.0002563166,0.0012427019,0.0037823927,0.00021779761,0.0009960681,0.00043313325,0.00077957223,0.0047932398],"category_scores_gemma":[0.008674813,0.00013370988,0.0007670723,0.005478594,0.00039179053,0.0009389861,0.00039596154,0.00035218924,0.00055843126],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003310292,0.00013926564,0.016660105,0.24872455,0.0018452271,0.007185075,0.0012122808,0.00023666784,0.0069648568,0.0011419794,0.015583979,0.6969958],"study_design_scores_gemma":[0.0018127101,0.0048183,0.1445656,0.21273677,0.01420768,0.047355354,0.0027098444,0.00051113503,0.00874826,0.0020252666,0.5602818,0.00022727296],"about_ca_topic_score_codex":0.0007960397,"about_ca_topic_score_gemma":0.0018207091,"teacher_disagreement_score":0.0047932398,"about_ca_system_score_codex":0.0004858268,"about_ca_system_score_gemma":0.001081705,"threshold_uncertainty_score":0.01603496},"labels":[],"label_agreement":null}]}